Burning biotech questions: An interim analysis

In January, STAT’s Damian Garde and Adam Feuerstein compiled a list of the biotech questions we most wanted answered. Now, half a year later, some have been resolved — and we’re still cogitating over the rest.

Take Regeneron, for instance: We asked whether the Dupixent commercial launch in asthma could mirror the drug’s strong performance with atopic dermatitis. Turns out the monoclonal antibody is a bit of a sleeper hit — heading for blockbuster, most likely, but taking its time. Meanwhile, Regeneron’s stock is down 19 percent this year, and much of the company’s revenues come from sales to Medicaid. So now, we’re looking to Washington for some guidance on how drug pricing policy will play out.

We've got questions on nine other companies. And, like we said, some answers, too.